Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Lead Pharma Holding B.V.. (6/18/15). "Press Release: Lead Pharma Appoints Three Seasoned Industry Experts to its Supervisory Board. Jan Egberts, M.D., Ir. Jan van der Hoeven and Daan van den Noort, M.D. Join Newly Established Supervisory Board". Nijmegen

Organisations Organisation Lead Pharma Holding B.V.
  Organisation 2 Agendia (Group)
  Today Agendia B.V.
Products Product ROR gamma inhibitor (orphan nuclear receptor gamma inhibitor)
  Product 2 drug development
Persons Person Egberts, Jan Hendrik (OctoPlus 201101– CEO)
  Person 2 van Gorp, Ad (Cytura Therapeutics 201903– CEO + Co-Founder before Lead Pharma 201502 CEO + Co-founder)
     


Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has appointed Dr. Jan Egberts, Ir. Jan van der Hoeven and Daan van den Noort to its newly established Supervisory Board.

Jan Egberts, M.D., has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as Chief Executive Officer of Agendia Inc., a molecular diagnostics company. Prior to this, Dr. Egberts was Chief Executive Officer of OctoPlus N.V., a specialty pharmaceutical company, which was acquired by Dr. Reddy’s Laboratories Ltd. In 2013. He also served as a Senior Healthcare Advisor for 3i Group plc and as President, Chairman and Chief Executive Officer of NovaDel Pharmaceuticals Inc. In addition, he held multiple business development and general management positions at Johnson & Johnson, Merck & Co. and Mölnlycke Health Care. Dr. Egberts, who graduated from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford, also serves on the Supervisory Board of several other private and public healthcare companies.

Ir. Jan van der Hoeven brings more than 30 years of experience in the biopharmaceutical industry. In 1983, he was co-founder of the CRO NOTOX, which he also headed until it was acquired by WIL Research Laboratories in 2006. In addition, since 1988 he has advised numerous life sciences companies, e.g. as a member of the Supervisory Board. He is also an ambassador of Wageningen University (Wageningen, The Netherlands). Before founding NOTOX, he worked as a scientist at Wageningen University for six years with emphasis on the relation of food and cancer. He (co-)authored over 30 scientific publications and has been awarded the EEMS Young Scientist Award in 1985. In 2003, he received the price for entrepreneurship from Wageningen University. Ir. van der Hoeven graduated from Wageningen University.

Daan van den Noort, M.D., brings over 25 years of experience as a manager and venture capitalist in the pharmaceutical and biotechnology industry in Europe. Among others, he served as General Manager for Genentech, Asta Medica, and Ferring in The Netherlands. From 2001 to 2011, he acted as the Chief investment Officer of the Biotech Turnaround Fund. He serves on several international boards of investment companies active in the biopharmaceutical industry. Mr. van den Noort holds an MD degree from the Free University of Amsterdam.

“We are delighted to attract three highly qualified healthcare professionals with extensive industry expertise to our Supervisory Board," said Ad van Gorp, co-founder and Chief Executive Officer of Lead Pharma. “Each of them brings significant experience in pharmaceutical drug development and commercialization and clinical as well as business development.” He added that the appointments will help Lead Pharma to strengthen its position as a trusted partner for pharma companies seeking high-quality compounds and projects against competitive targets in important indications.


# # #


About Lead Pharma

Lead Pharma is a biopharmaceutical company focusing on the discovery and development of innovative medicines for the treatment of autoimmune diseases and cancer. Lead Pharma’s drug discovery engine combines medicinal, structural, and computational chemistry with molecular pharmacology, cell and tissue-based pharmacology. Thereby, the company aims to identify first and / or best-in-class small molecule drugs. Based in Nijmegen and Oss, the Netherlands, Lead Pharma is privately owned and is financed by Biox Biosciences, Participatiemaatschappij Oost Nederland N.V. (PPM Oost), Life Sciences & Health Fund B.V. (BOM Capital), and Technostartersfonds Zuid Nederland B.V. For more information visit: www.leadpharma.com


Contact:

Media Inquiries:
akampion
Dr. Ludger Wess or Ines-Regina Buth
Tel.: +49 (0)40 88 16 59 64 / +49 (0)30 2363 2768
info(at)akampion.com

Company Inquiries:
Lead Pharma Holding B.V.
Dr. Ad van Gorp, CEO
Tel.: +31 412 782999
ad.vangorp@leadpharma.com

   
Record changed: 2016-01-10

Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Lead Pharma Holding B.V.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81




» top